VAX 125

Drug Profile

VAX 125

Alternative Names: Flagellin.HuHA; Hemagglutinin (HA)-based seasonal influenza vaccine - VaxInnate; STF2.HA1 (SI) - VaxInnate; VAX125

Latest Information Update: 11 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator VaxInnate
  • Class Influenza A vaccines; Recombinant fusion proteins
  • Mechanism of Action Immunostimulants; Toll-like receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Influenza A virus infections

Most Recent Events

  • 27 Aug 2015 No recent reports on development identified - Phase-II for Influenza-A virus infections (In the elderly) in USA (IM)
  • 19 Dec 2011 VaxInnate's recombinant seasonal and pandemic influenza vaccines licensed to CJ CheilJedang Corporation exclusively in South Korea, and non-exclusively in certain South-East Asia countries, excluding China
  • 25 Jul 2011 VaxInnate completes a phase II trial in Influenza A virus infections (prevention) in patients aged ≥65 years in USA (NCT00966238)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top